A new osteoporosis injection, an expanded label for Keytruda & more: 4 recent FDA approvals

Four drugs or medical devices approved by the FDA since April 1:

Advertisement

1. Evenity, a monthly injection, is approved to treat osteoporosis is postmenopausal women at high risk of bone fracture.

2. Dovato is a two-drug, fixed-dose complete regimen for HIV patients who have not received antiretroviral treatment.

3. The FDA expanded indication of Ibrance, a metastatic breast cancer treatment,  to include male patients.

4. The FDA expanded the label for Keytruda, a cancer immunotherapy drug, as monotherapy for the first-line treatment of patients with stage 3 non-small cell lung cancer who are not able to receive surgical resection of chemoradiation.

More articles on supply chain:
FDA braces for medical device shortages: 9 things to know
Reports of breast implant ‘illness’ spur FDA safety review
5 supply chain technologies to watch

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.